Analysis of 287 children with type 1 diabetes over 6.2 years revealed that 32% experienced lipoprotein(a) fluctuations exceeding 50% of their peak values, with levels peaking between ages 10-13 before declining. Nearly 12% of participants crossed the critical 300 mg/L cardiovascular risk threshold during follow-up, demonstrating clinically meaningful variability in this supposedly stable biomarker. This challenges the established paradigm that Lp(a) remains constant throughout life, justifying single lifetime testing. The finding carries significant implications for cardiovascular risk management in high-risk populations. Children with type 1 diabetes already face elevated lifetime cardiovascular disease risk, making accurate risk stratification crucial for early intervention strategies. Current guidelines recommend one-time Lp(a) testing, but this data suggests repeated measurements during adolescence could prevent misclassification of up to 12% of patients. The observed seasonal variation and age-related patterns indicate biological factors beyond genetics influence Lp(a) levels during development. However, this preprint awaits peer review, and the single-center design limits generalizability. The findings represent an important challenge to current clinical practice, potentially requiring updated guidelines for cardiovascular risk assessment in pediatric diabetes care.